目的 探讨津力达颗粒联合度拉糖肽注射液治疗2型糖尿病临床疗效。方法 选取2019年6月-2020年3月河南理工大学第一附属医院收治的2型糖尿病患者92例，根据用药的差别分成对照组（46例）和治疗组（46例）。对照组静脉滴注度拉糖肽注射液，起始剂量0.75 mg/周，最大剂量1.5 mg/周；治疗组在对照组的基础上口服津力达颗粒，9 g/次，3次/d。两组患者均经8周治疗。观察两组患者临床疗效，同时比较治疗前后两组患者空腹血糖（FPG）、糖化血红蛋白（HbA1c）、餐后2 h血糖（2 h PG）和胰岛素（FINS）水平，血糖波动情况，及血清单核细胞趋化蛋白1（MCP-1）、γ-谷氨酰转移酶（γ-GT）、血管细胞黏附分子1（VCAM-1）、白细胞介素-1β（IL-1β）和瘦素（LP）水平。结果 治疗后，对照组临床有效率为80.43%，显著低于治疗组的97.87%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者FPG、HbAlc、2 h PG、FINS、血糖波动指标，及血清MCP-1、γ-GT、VCAM-1、IL-1β和LP水平均显著降低（P<0.05），且治疗组患者明显低于对照组（P<0.05）。结论 津力达颗粒联合度拉糖肽注射液治疗2型糖尿病可有效控制患者血糖水平，具有一定的临床推广应用价值。

Objective To explore the therapeutic effect of Jinlida Granules combined with dulaglutide in treatment of type 2 diabetes mellitus. Methods Patients (92 cases) with type 2 diabetes mellitus in the First Affiliated Hospital of Henan Polytechnic University from June 2019 to March 2020 were divided into control (46 cases) and treatment (46 cases) groups based on different treatments. Patients in the control group were iv administered with Dulaglutide Injection, the initial dose was 0.75 mg/week, and the maximum dose was 1.5 mg/week. Patients in the treatment group were po administered with Jinlida Granules on the basis of the control group, 9 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the level of FPG, HbA1c, 2 h PG, FINS, blood glucose fluctuation, and the serum content of MCP-1, γ-GT, VCAM-1, IL-1β and LP in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 80.43%, which was significantly lower than 97.87% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the level of FPG, HbA1c, 2 h PG, FINS, blood glucose fluctuation, and the serum content of MCP-1, γ-GT, VCAM-1, IL-1β and LP in two groups were significantly decreased (P < 0.05), and these indexes in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Jinlida Granules combined with dulaglutide in treatment of type 2 diabetes mellitus can effectively control the blood glucose level, which has a certain clinical application value.

R977

河南省医学科技攻关计划项目（LHGJ20191356）